EAGLE PHARMACEUTICALS, INC. (EGRX) vs. ABBOTT LABORATORIES (ABT) Stock Comparison & Valuation | Edwyn

Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

EAGLE PHARMACEUTICALS, INC. (EGRX) vs. ABBOTT LABORATORIES (ABT) Stock Comparison & Valuation | Edwyn

Updated 2026-08-01 12:10 UTC

This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.

EGRX screens as radically cheaper than ABT on standard multiples, but the valuation gap is harder to interpret because EGRX’s market cap appears to reflect distress-like pricing despite strong recent growth and high ROIC.

Actionable Takeaway

If you believe EGRX can sustain its high growth and translate that into stable cash generation without worsening quality metrics, then the stock looks deeply mispriced versus both ABT and the DCF range because the current price is pinned near its historical low despite much stronger growth and ROIC.

EGRX trades at an extreme discount versus ABT on both earnings and sales multiples, with the current price at $0.37 versus an implied P/E price of $77.57. However, the comparison is distorted by EGRX’s near-zero reported valuation multiples and the fact that its historical band is only $0.33-$0.41, suggesting the market is anchoring EGRX near distressed or event-driven pricing rather than ABT parity.

Supporting Metrics

Key Risks

Altman Z-Score of 2.07 indicates only moderate financial health, which could limit rerating potential.
Piotroski F-Score of 5/9 suggests mixed fundamental quality and no clear turnaround confirmation.
The valuation gap may reflect company-specific or event-driven risk, as the current price of $0.37 sits within the historical band of $0.33-$0.41 despite a DCF range of $41.53-$56.19.